Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study intends to measure fibrinogen plasma levels during the first 24 hrs in cardiac and thoracic surgical patients who undergo surgical procedures using extracorporeal circulation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fibrinogen plasma level in CABG | In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level |
| |
| Fibrinogen plasma level in AVR | In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level |
| |
| Fibrinogen plasma level in AAR | In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fibrinogen plasma level | Procedure | At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM. |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma fibrinogen concentration | Conventional (Clauss) and thromboelastometric measurement (FIBTEM) | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Periprocedural thromboembolic complications | through study completion, an average of 1 year | |
| Thoracic drain loss | Measurement of the amount of blood collected by the thoracic drain (ml) | through study completion, an average of 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients undergoing cardiac surgery with extracorporeal bypass
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gabor Erdoes, MD | University of Bern | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Bern | Bern | 3010 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D000987 | Antisocial Personality Disorder |
| ID | Term |
|---|---|
| D010554 | Personality Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood containing all components
| In-hospital mortality | through study completion, an average of 1 year |
| Intensive Care Unit (ICU) length of stay | through study completion, an average of 1 year |
| Platelet count | Measurement of platelet count in the laboratory | through study completion, an average of 1 year |
| Prothrombin time (Quick) | Measurement of Quick in the laboratory | through study completion, an average of 1 year |
| Activated partial thromboplastin time (aPTT) | Measurement of aPTT in the laboratory | through study completion, an average of 1 year |
| Thromboelastometric (ROTEM) parameters (e.g., INTEM, EXTEM, HEPTEM) | Measurement of ROTEM parameter (unit mm) in the laboratory | through study completion, an average of 1 year |
| Thrombin concentration | Thrombin concentration in the plasma as measured in the laboratory | through study completion, an average of 1 year |